Literature DB >> 23817838

Should patients with papillary microcarcinoma undergo radioiodine ablation?

Leonard Wartofsky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23817838     DOI： 10.1007/s12020-013-0010-3

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  15 in total

1.  Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients.

Authors:  Ling Zhang; Wen-Jun Wei; Qing-Hai Ji; Yong-Xue Zhu; Zhuo-Ying Wang; Yu Wang; Cai-Ping Huang; Qiang Shen; Duan-Shu Li; Yi Wu
Journal:  J Clin Endocrinol Metab       Date:  2012-02-08       Impact factor: 5.958

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.

Authors:  Maria Grazia Castagna; Fabio Maino; Claudia Cipri; Valentina Belardini; Alexandra Theodoropoulou; Gabriele Cevenini; Furio Pacini
Journal:  Eur J Endocrinol       Date:  2011-07-12       Impact factor: 6.664

4.  Management of papillary thyroid microcarcinoma: primum non nocere!

Authors:  Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2013-04       Impact factor: 5.958

Review 5.  A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer.

Authors:  R Michael Tuttle; Genevieve Rondeau; Nancy Y Lee
Journal:  Cancer Control       Date:  2011-04       Impact factor: 3.302

6.  Analysis of the clinicopathologic features of papillary thyroid microcarcinoma based on 7-mm tumor size.

Authors:  Kwan Ju Lee; Yun Jung Cho; Say Jun Kim; Sang Chul Lee; Jeong Goo Kim; Chang Joon Ahn; Dong Ho Lee
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

7.  Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression.

Authors:  Greta Gandolfi; Valentina Sancisi; Federica Torricelli; Moira Ragazzi; Andrea Frasoldati; Simonetta Piana; Alessia Ciarrocchi
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

8.  Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Daniela Capacchione; Anna Nardelli; Francesco Barbato; Antonio Nappi; Teresa Pellegrino; Giovanni Storto
Journal:  Endocrine       Date:  2013-03-28       Impact factor: 3.633

9.  Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries.

Authors:  Pasqualino Malandrino; Gabriella Pellegriti; Marco Attard; Maria Antonia Violi; Carla Giordano; Laura Sciacca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Clin Endocrinol Metab       Date:  2013-03-12       Impact factor: 5.958

10.  Prognostic parameters for recurrence of papillary thyroid microcarcinoma.

Authors:  Tae Yong Kim; Suck Joon Hong; Jung Min Kim; Won Gu Kim; Gyungyub Gong; Jin Sook Ryu; Won Bae Kim; Sung-Cheol Yun; Young Kee Shong
Journal:  BMC Cancer       Date:  2008-10-14       Impact factor: 4.430
View more
  2 in total

1.  Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma.

Authors:  Ji Soo Choi; Eun-Kyung Kim; Hee Jung Moon; Jin Young Kwak
Journal:  Endocrine       Date:  2014-05-25       Impact factor: 3.633

2.  The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.

Authors:  Daniele Barbaro; Roberto Mario Incensati; Gabriele Materazzi; Giuseppe Boni; Mariano Grosso; Erica Panicucci; Paola Lapi; Cristina Pasquini; Paolo Miccoli
Journal:  Endocrine       Date:  2013-08-08       Impact factor: 3.633
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.